Back to Search
Start Over
Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry
- Source :
- Annals of the Rheumatic Diseases, Annals of the Rheumatic Diseases, BMJ Publishing Group, 2016, 75 (6), pp.1108-1113. ⟨10.1136/annrheumdis-2015-207362⟩, Annals of the Rheumatic Diseases, 2016, 75 (6), pp.1108-1113. ⟨10.1136/annrheumdis-2015-207362⟩
- Publication Year :
- 2016
- Publisher :
- HAL CCSD, 2016.
-
Abstract
- ObjectivesLittle data are available regarding the rate and predicting factors of serious infections in patients with rheumatoid arthritis (RA) treated with abatacept (ABA) in daily practice. We therefore addressed this issue using real-life data from the Orencia and Rheumatoid Arthritis (ORA) registry.MethodsORA is an independent 5-year prospective registry promoted by the French Society of Rheumatology that includes patients with RA treated with ABA. At baseline, 3 months, 6 months and every 6 months or at disease relapse, during 5 years, standardised information is prospectively collected by trained clinical nurses. A serious infection was defined as an infection occurring during treatment with ABA or during the 3 months following withdrawal of ABA without any initiation of a new biologic and requiring hospitalisation and/or intravenous antibiotics and/or resulting in death.ResultsBaseline characteristics and comorbidities: among the 976 patients included with a follow-up of at least 3 months (total follow-up of 1903 patient-years), 78 serious infections occurred in 69 patients (4.1/100 patient-years). Predicting factors of serious infections: on univariate analysis, an older age, history of previous serious or recurrent infections, diabetes and a lower number of previous anti-tumour necrosis factor were associated with a higher risk of serious infections. On multivariate analysis, only age (HR per 10-year increase 1.44, 95% CI 1.17 to 1.76, p=0.001) and history of previous serious or recurrent infections (HR 1.94, 95% CI 1.18 to 3.20, p=0.009) were significantly associated with a higher risk of serious infections.ConclusionsIn common practice, patients treated with ABA had more comorbidities than in clinical trials and serious infections were slightly more frequently observed. In the ORA registry, predictive risk factors of serious infections include age and history of serious infections.
- Subjects :
- Adult
Male
medicine.medical_specialty
Multivariate analysis
Immunology
Comorbidity
Opportunistic Infections
General Biochemistry, Genetics and Molecular Biology
Abatacept
Arthritis, Rheumatoid
03 medical and health sciences
Immunocompromised Host
0302 clinical medicine
Rheumatology
Risk Factors
Internal medicine
Diabetes mellitus
medicine
Immunology and Allergy
Humans
[SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology
030212 general & internal medicine
Registries
Aged
030203 arthritis & rheumatology
Univariate analysis
business.industry
Age Factors
Middle Aged
medicine.disease
Connective tissue disease
3. Good health
Surgery
Clinical trial
Rheumatoid arthritis
Antirheumatic Agents
Female
France
business
Immunosuppressive Agents
[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 00034967 and 14682060
- Database :
- OpenAIRE
- Journal :
- Annals of the Rheumatic Diseases, Annals of the Rheumatic Diseases, BMJ Publishing Group, 2016, 75 (6), pp.1108-1113. ⟨10.1136/annrheumdis-2015-207362⟩, Annals of the Rheumatic Diseases, 2016, 75 (6), pp.1108-1113. ⟨10.1136/annrheumdis-2015-207362⟩
- Accession number :
- edsair.doi.dedup.....847c66f093f6f752627bc7e0feda9847
- Full Text :
- https://doi.org/10.1136/annrheumdis-2015-207362⟩